血清HE4、CA125联合检测对卵巢上皮性恶性肿瘤的诊断价值及其与临床特征的关系  

The diagnostic value of serum HE4 and CA125 for ovarian epithelial malignant tumor and its relationship with clinical characteristics

作　　者：孙晓[1] 牛东升 徐恩松 董阳 SUN Xiao;NIU Dongsheng;XU Ensong;DONG Yang(Department of Oncology,2Department of Radiotherapy,Tumor Hospital of Nanyang Central Hospital,Nanyang 473000,He＇ nan,China)

机构地区：[1]南阳市中心医院肿瘤医院肿瘤内科,河南南阳4730000 [2]南阳市中心医院肿瘤医院放疗科,河南南阳4730000

出　　处：《癌症进展》2018年第8期1016-1019,共4页Oncology Progress

摘　　要：目的探讨血清人附睾分泌蛋白4(HE4)、糖类抗原125(CA125)联合检测对卵巢上皮性恶性肿瘤的临床诊断价值及其与患者临床特征的关系。方法选取60例卵巢上皮性恶性肿瘤患者(恶性组)和120例卵巢良性病变患者(良性组)作为研究对象,检测两组患者的血清HE4、CA125水平,分析血清HE4、CA125水平与卵巢上皮性恶性肿瘤病理类型、FIGO分期及分化程度的关系,探究两项指标单独及联合检测对卵巢上皮性恶性肿瘤的诊断价值。结果恶性组患者的血清HE4、CA125水平分别为(161.3±48.9)pmol/L、(59.3±29.8)U/ml,均明显高于良性组患者的(87.3±26.1)pmol/L、(18.4±9.0)U/ml(P﹤0.01)。血清HE4单独诊断卵巢上皮性恶性肿瘤的灵敏度为63.3%,特异度为50.0%;CA125单独诊断卵巢上皮性恶性肿瘤的灵敏度为53.3%,特异度为45.8%;血清HE4+CA125联合诊断卵巢上皮性恶性肿瘤的灵敏度为91.7%,特异度为62.5%。血清HE4的阳性表达水平与卵巢上皮性恶性肿瘤患者的FIGO分期和分化程度有关(P﹤0.05),与病理类型无关(P﹥0.05);血清CA125的阳性表达水平与卵巢上皮性恶性肿瘤患者的病理类型、FIGO分期和分化程度均有关(P﹤0.05)。结论血清HE4、CA125联合检测对卵巢上皮性恶性肿瘤具有较高的诊断价值,较单一指标检测提高了灵敏度和特异度,值得临床推广应用。Objective To investigate the clinical value of serum human epididymal secretory protein 4 （HE4） and car- bohydrate antigen 125 （CA125） levels in the diagnosis of ovarian epithelial malignant tumors and its relationship with clinical characteristics. Method 60 patients with ovarian epithelial malignant tumor （malignant group） and 120 patients with benign ovarian diseases （benign group） were collected. The serum HE4 and CA 125 levels of all patients were detect- ed and the relationships of serum HE4 and CA125 in ovarian cancer with the pathological type, FIGO stage and differenti-ation degree were analyzed. The alone and the combination diagnostic value of the two indexes for ovarian epithelial ma- lignant cancer were evaluated. Result The serum HE4, CA125 levels in malignant group were （161.3±448.9） pmol/L and （59.3±29.8） U/ml, which were significantly higher than those [（87.3±26.1） pmol/L, （18.44±9.0） U/ml] in benign group （P〈 0.01）. The sensitivity and specificity of serum HE4 alone in differential diagnosis of ovarian epithelial malignant cancer were 63.3% and 50.0%; the sensitivity and specificity of CA125 in differential diagnosis of ovarian epithelial malignant cancer were 53.3% and 45.8%; the sensitivity and specificity of serum HE4 and CA125 combination in the differential di- agnosis of ovarian epithelial malignant cancer were 91.7% and 62.5%. The positive expression rate of serum HE4 in pa- tients with ovarian epithelial malignant cancer was significantly related to FIGO staging and degree of differentiation （P〈 0.05）, but not related to pathological type （P〉0.05）; serum CA125 level in patients with ovarian epithelial malignant can- cer was related to pathological type, FIGO stage and degree of differentiation （P〈0.05）. Conclusion The combined use of serum HE4 and CA 125 has high value in differential diagnosis of ovarian epithelial malignant cancer, which is worthy of clinical application with higher sensitivity and specificity compared to sing

关 键 词：人附睾分泌蛋白4 糖类抗原125 卵巢上皮性恶性肿瘤 卵巢良性病变 临床特征 

分 类 号：R737.31[医药卫生—肿瘤]